Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03906539|
Recruitment Status : Recruiting
First Posted : April 8, 2019
Last Update Posted : June 9, 2020
|Condition or disease||Intervention/treatment||Phase|
|Dyslipidemias||Drug: Atorvastatin 10mg Dietary Supplement: Virgin Coconut Oil (VCO) Other: Placebo||Phase 4|
Dyslipidemia is a well-established risk factor for cardiovascular (CV) diseases. Lipid abnormalities, including high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C), are independent predictors of CV disease. The National Cholesterol Education Program Adult Treatment Panel III (ATP III) guideline and the American College of Cardiology (ACC) and American Heart Association (AHA) guideline recommend the use of statins for primary prevention based on a patient's cardiovascular risk profile and low-density lipoprotein cholesterol (LDL-C) level. However, statin therapy may be insufficient for patients with mixed dyslipidemia, especially those with metabolic syndromes. While the addition of niacin, fibrate or ezetimibe may be useful in this setting, the combination therapy may lead to more adverse drug reactions.
Virgin Coconut Oil (VCO), a nutraceutical, is an oil obtained from the fresh, mature kernel of the coconut by mechanical or natural means, with or without the use of heat and without undergoing chemical refining and it contains a considerable amount of medium-chain fatty acids similar to those in mother's milk. The beneficial effects of VCO in the reduction of cardiovascular risk have been proved from previous animal and clinical studies. The previous study demonstrated the potential beneficiary effect of VCO in lowering lipid levels in serum and LDL oxidation by physiological oxidants and this property of VCO was attributed to the biologically active polyphenol components present in the oil. It has been also demonstrated the hypolipidemic effect of VCO through activation of lipoprotein lipase, lecithin cholesterol acyltransferase and enhanced formation of bile acids. It was found that isolated polyphenols from VCO can prevent cadmium-induced lipid abnormalities and cardiovascular risk ratios by improving antioxidant defence systems. VCO may improve cardiovascular and hepatic complications in obesity. The findings from another study suggest a beneficial eﬀect of VCO on lipid profile, renal status, hepatic antioxidant defence system, and cardiovascular risk indices in rats. It has been observed that VCO increased HDL-C level in patients with coronary artery disease (CAD). In a randomized crossover trial, it was found that daily consumption of VCO in young healthy adults significantly increased high-density lipoprotein cholesterol without any safety issues.
Our literature search revealed that to date, no clinical trial evaluated the potential of VCO as an add-on hypolipidemic agent in patients suffering from dyslipidemia. So, the present clinical trial has been designed to evaluate the effect of VCO on cardiometabolic parameters as an add-on with statins in patients with dyslipidemia.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia: A Randomized, add-on, Placebo-controlled Clinical Trial|
|Actual Study Start Date :||May 22, 2019|
|Estimated Primary Completion Date :||January 31, 2021|
|Estimated Study Completion Date :||March 31, 2021|
Placebo Comparator: Control Group
The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
Drug: Atorvastatin 10mg
Atorvastatin 10 mg per day
Placebo capsule - 1 capsule per day
Experimental: VCO Group
The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
Drug: Atorvastatin 10mg
Atorvastatin 10 mg per day
Dietary Supplement: Virgin Coconut Oil (VCO)
Capsule VCO (1000 mg/day)
- Change in serum High Density Lipoprotein (HDL) [ Time Frame: Baseline and 8 weeks ]Will be measured by autoanalyser
- Change in serum Lipoprotein (a) [ Time Frame: Baseline and 8 weeks ]Will be measured by ELISA
- Change in Atherogenic index [ Time Frame: Baseline and 8 weeks ]Ratio of LDL cholesterol and HDL cholesterol
- Change in Coronary risk index [ Time Frame: Baseline and 8 weeks ]Ratio of total cholesterol and HDL cholesterol
- Change in Cardiovascular risk index [ Time Frame: Baseline and 8 weeks ]Ratio of triglyceride and HDL cholesterol
- Change in visceral fat [ Time Frame: Baseline and 8 weeks ]Will be analysed by by digital body fat analyser
- Change in lipid peroxidation [ Time Frame: Baseline and 8 weeks ]Thiobarbituric acid reactive substances (TBARS) will be estimated by spectrofluorometric method
- Change in serum Low Density Lipoprotein (LDL) [ Time Frame: Baseline and 8 weeks ]Will be measured by autoanalyser
- Change in serum Very Low Density Lipoprotein (VLDL) [ Time Frame: Baseline and 8 weeks ]Will be measured by autoanalyser
- Change in serum total cholesterol [ Time Frame: Baseline and 8 weeks ]Will be measured by autoanalyser
- Change in serum triglyceride [ Time Frame: Baseline and 8 weeks ]Will be measured by autoanalyser
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03906539
|Contact: RITUPARNA MAITI, MDfirstname.lastname@example.org|
|Contact: RASHMI R MOHANTY, MDemail@example.com|
|Bhubaneshwar, Odisha, India, 751019|
|Contact: RITUPARNA MAITI, MD firstname.lastname@example.org|
|Sub-Investigator: RASHMI R MOHANTY, MD|